GlobeNewswire - Licensing Agreements Contains the last 20 releases uuid:927ff8b4-1f64-452c-8571-c837d56b3c35;id=14868 2021-03-04T20:33:36Z newsdesk@globenewswire.com (NewsDesk) http://www.yebxqs.cn/LegacyRss?Length=4 newsdesk@globenewswire.com http://www.yebxqs.cn/news-release/2021/03/04/2187559/0/en/Max-Sound-Corp-announced-today-the-official-signing-of-its-first-major-fee-based-license-for-MAXD-HD-Audio-Technology-in-a-Joint-Venture-Agreement-with-Tip-Solutions-Inc.html Max Sound Corp. announced today the official signing of?its first major, fee-based, license for MAXD HD Audio? Technology in a Joint Venture Agreement with Tip Solutions, Inc. 2021-03-04T20:33:36Z 2021-03-05T14:17:41Z SAN DIEGO, March 04, 2021 (GLOBE NEWSWIRE) -- Max Sound Corp.?(OTC:?MAXD) announced today that it has signed a Joint Venture Agreement with TIP Solutions, that brings their revolutionary technologies to market together with game-changing Patented and Trademarked MAX-D HD Audio and TIP's Cutting Edge Call Management Platform.

]]>
2187559 en GlobeNewswire Inc. Max Sound Corporation Thu, 04 Mar 2021 20:33 GMT Business Contracts Licensing Agreements
http://www.yebxqs.cn/news-release/2021/03/04/2187006/0/en/Verrica-Pharmaceuticals-Reports-Fourth-Quarter-and-Full-Year-2020-Financial-Results.html Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2020 Financial Results 2021-03-04T12:30:00Z 2021-03-05T14:17:41Z – FDA accepts resubmitted NDA for VP-102 for the treatment of molluscum contagiosum with PDUFA goal date of June 23, 2021 –

]]>
2187006 en GlobeNewswire Inc. Verrica Pharmaceuticals Thu, 04 Mar 2021 12:30 GMT Earnings Releases and Operating Results Licensing Agreements
http://www.yebxqs.cn/news-release/2021/03/02/2185157/0/en/APPlife-Digital-Solutions-Inc-Executes-Definitive-E-Commerce-Platform-License-Agreement-with-Global-Hemp-Service-LLC.html APPlife Digital Solutions, Inc. Executes Definitive E-Commerce Platform License Agreement with Global Hemp Service LLC 2021-03-02T12:30:00Z 2021-03-05T14:17:41Z SAN FRANCISCO, March 02, 2021 (GLOBE NEWSWIRE) -- APPlife Digital Solutions, Inc. (OTCQB: ALDS) (“APPlife”, the Company”), a business incubator and portfolio manager that invests in and creates e-commerce and cloud-based solutions announced today that it has executed its previously announced letter of intent and signed a definitive agreement (“Agreement”) with Global Hemp Service LLC (“Global”). The Agreement provides Global with a perpetual, royalty-free, non-exclusive license to use APPlife’s market-ready and mobile website e-commerce platform to market, distribute, and sell its hemp, cannabidiol (“CBD”) and other related B2B and B2C products.

]]>
2185157 en GlobeNewswire Inc. APPlife Digital Solutions, Inc. Tue, 02 Mar 2021 12:30 GMT Licensing Agreements Product / Services Announcement Mobile Apps cloud-based solutions cannabidoil hemp e-commerce CBD iols B2BCHX Rooster Essentials Men's Subscription Service
http://www.yebxqs.cn/news-release/2021/03/02/2185134/0/en/Kraig-Biocraft-Laboratories-Announces-Spider-Silk-Patent-Granted-in-Canada.html Kraig Biocraft Laboratories Announces Spider Silk Patent Granted in Canada 2021-03-02T12:05:00Z 2021-03-05T14:17:41Z ANN ARBOR, Mich., March 02, 2021 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company" or "Kraig Labs"), the biotechnology company focused on the development and commercialization of spider silk, announces that the University of Notre Dame has been granted a Canadian patent on spider silk technology developed pursuant to the collaborative research agreement with Kraig. This patent further protects Kraig's growing portfolio of spider silk Intellectual Property.

]]>
2185134 en GlobeNewswire Inc. Kraig Biocraft Laboratories Tue, 02 Mar 2021 12:05 GMT Patents Licensing Agreements Kraig Labs NASDAQ patent Canada breakthrough biotech KBLB high tech tech gene-editing spider silk USPTO environment textile polymers
http://www.yebxqs.cn/news-release/2021/03/02/2185067/0/en/PharmaTher-Expands-to-Neuromuscular-Diseases-with-Exclusive-License-Agreement-for-Ketamine-in-the-Treatment-of-Lou-Gehrig-s-Disease.html PharmaTher Expands to Neuromuscular Diseases with Exclusive License Agreement for Ketamine in the Treatment of Lou Gehrig’s Disease 2021-03-02T12:00:00Z 2021-03-05T14:17:41Z TORONTO, March 02, 2021 (GLOBE NEWSWIRE) -- Newscope Capital Corporation (CSE: PHRM) (OTCQB: PHRRF), who through its wholly-owned subsidiary, PharmaTher Inc. (“PharmaTher”), is a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals, is pleased to announce that PharmaTher has entered into an exclusive license agreement with The University of Kansas for the development and commercialization for the intellectual property of ketamine in the treatment amyotrophic lateral sclerosis (“ALS”), also known as Lou Gehrig's disease.

]]>
2185067 en GlobeNewswire Inc. Newscope Capital Corporation Tue, 02 Mar 2021 12:00 GMT Health Licensing Agreements Product / Services Announcement
http://www.yebxqs.cn/news-release/2021/03/02/2184801/0/en/Knight-Therapeutics-Announces-Canadian-Commercial-Launch-of-IBSRELA-New-Innovative-Treatment-for-Irritable-Bowel-Syndrome-with-Constipation.html Knight Therapeutics Announces Canadian Commercial Launch of IBSRELA? - New Innovative Treatment for Irritable Bowel Syndrome with Constipation 2021-03-02T00:04:40Z 2021-03-05T14:17:41Z MONTREAL, March 01, 2021 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD), (“Knight”) a pan-American (ex-USA) specialty pharmaceutical company, announced today the Canadian commercial availability of IBSRELA (tenapanor), a first-in-class therapy for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults. Knight has the exclusive right to commercialize IBSRELA in Canada under the terms of a license agreement entered into with Ardelyx, Inc. (NASDAQ: ARDX) in March 2018, which license agreement also provides Knight with exclusive rights to commercialize tenapanor for hyperphosphatemia in Canada.?? IBSRELA was approved by Health Canada on April 15, 2020 and is now covered by most private insurance companies in Canada.

]]>
2184801 en GlobeNewswire Inc. Knight Therapeutics Tue, 02 Mar 2021 00:05 GMT Health Product / Services Announcement Licensing Agreements
http://www.yebxqs.cn/news-release/2021/03/02/2184801/0/fr/Th%C3%A9rapeutique-Knight-annonce-le-lancement-commercial-canadien-de-IBSRELA-MC-un-nouveau-traitement-innovant-du-syndrome-de-c%C3%B4lon-irritable-avec-constipation.html Thérapeutique Knight annonce le lancement commercial canadien de IBSRELA(MC) — un nouveau traitement innovant du syndrome de c?lon irritable avec constipation 2021-03-02T00:04:40Z 2021-03-05T14:17:41Z MONTRÉAL, 01 mars 2021 (GLOBE NEWSWIRE) -- Thérapeutique Knight inc. (TSX : GUD) (??Knight??), société pharmaceutique spécialisée panaméricaine (ex-éU), a annoncé aujourd’hui la mise en marché au Canada de IBSRELA (tenapanor), thérapie de pointe pour le traitement du syndrome du c?lon irritable avec constipation (SCI-C) chez les adultes. Knight détient le droit exclusif de commercialisation de IBSRELA selon les modalités d’une entente de licence conclue avec Ardelyx, Inc. (NASDAQ : ARDX) en mars 2018, une entente de licence qui octroie également à Knight l’exclusivité des droits de commercialisation de tenapanor pour l’hyperphosphatémie au Canada. IBSRELA a été approuvé par Santé Canada en date du 15?avril 2020 et est désormais couvert par la majorité des compagnies d’assurance privées au Canada.

]]>
2184801 fr GlobeNewswire Inc. Knight Therapeutics Tue, 02 Mar 2021 00:05 GMT Health Product / Services Announcement Licensing Agreements
http://www.yebxqs.cn/news-release/2021/03/01/2184729/0/en/LEXEO-Therapeutics-Announces-License-Agreement-and-Consolidation-of-Comprehensive-Pre-clinical-Data-Package-to-Support-Cardiac-Friedreich-s-Ataxia-Gene-Therapy-Program-LX2006.html LEXEO Therapeutics Announces License Agreement and Consolidation of Comprehensive Pre-clinical Data Package to Support Cardiac Friedreich's Ataxia Gene Therapy Program (LX2006) 2021-03-01T21:30:00Z 2021-03-05T14:17:41Z LEXEO completes license of all intellectual property rights and pre-clinical data associated with Adverum Biotechnologies’ investigational Friedreich’s ataxia program

]]>
2184729 en GlobeNewswire Inc. LEXEO Therapeutics Mon, 01 Mar 2021 21:30 GMT Health Licensing Agreements Product / Services Announcement
http://www.yebxqs.cn/news-release/2021/03/01/2184648/0/en/Artizan-Biosciences-Closes-11-Million-Series-A-2-Financing-and-Enters-Option-and-License-Agreement-with-Biohaven-Therapeutics.html Artizan Biosciences Closes $11 Million Series A-2 Financing and Enters Option and License Agreement with Biohaven Therapeutics 2021-03-01T21:00:00Z 2021-03-05T14:17:41Z Agreement enables Biohaven to exercise option on up to three of Artizan’s candidates for the treatment of inflammatory bowel disease

]]>
2184648 en GlobeNewswire Inc. Artizan Biosciences, Inc. Mon, 01 Mar 2021 21:00 GMT Licensing Agreements
http://www.yebxqs.cn/news-release/2021/03/01/2184590/0/en/Sorrento-Therapeutics-and-Scilex-Holding-a-Majority-Owned-Subsidiary-Have-Entered-Into-an-Exclusive-Licensing-Term-Sheet-With-Aardvark-Therapeutics-to-Acquire-Its-ARD-301-For-the-T.html Sorrento Therapeutics and Scilex Holding, a Majority Owned Subsidiary, Have Entered Into an Exclusive Licensing Term Sheet With Aardvark Therapeutics to Acquire Its ARD-301 For the Treatment of Chronic Pain, Fibromyalgia, and Chronic Long Haul Covid Syndrome 2021-03-01T17:21:44Z 2021-03-05T14:17:41Z SAN DIEGO, Calif., March 01, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics (NASDAQ: SRNE, “Sorrento”) and Scilex Holdings Company (“Scilex”), a majority owned subsidiary of Sorrento, have entered into an exclusive licensing term sheet with Aardvark Therapeutics (“Aardvark”) to acquire Aardvark’s proprietary formulation, Delayed Burst Release Low Dose Naltrexone (DBR-LDN), or ARD-301, for the treatment of chronic pain, fibromyalgia, and chronic post-COVID syndrome (“long haul COVID” or “long COVID”) in multiple Phase 2 programs planned to be initiated this year.

]]>
2184590 en GlobeNewswire Inc. Sorrento Therapeutics, Inc. Mon, 01 Mar 2021 17:22 GMT Health Licensing Agreements Partnerships Sorrento Therapeutics Scilex holdings non-opioid Fibromyalgia
http://www.yebxqs.cn/news-release/2021/03/01/2184353/0/en/EnWave-Signs-Technology-Evaluation-and-License-Option-Agreement-with-Leading-Turkish-Dairy-Company-and-Announces-Equity-Incentive-Grant.html EnWave Signs Technology Evaluation and License Option Agreement with Leading Turkish Dairy Company and Announces Equity Incentive Grant 2021-03-01T14:00:00Z 2021-03-05T14:17:41Z VANCOUVER, British Columbia, March 01, 2021 (GLOBE NEWSWIRE) -- EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the “Company”)?announced today that it has signed a technology evaluation and license option agreement (the “TELOA”) with Süta? süt ürünleriI A.?. (“Süta?”), a leading Turkish dairy company. Süta? will evaluate EnWave’s proprietary Radiant Energy Vacuum (“REV?”) dehydration technology for the dehydration of premium dairy snacks and ingredients.

]]>
2184353 en GlobeNewswire Inc. EnWave Corporation Mon, 01 Mar 2021 14:00 GMT Licensing Agreements Dairy Canadian Exports Canadian Food Equipment
http://www.yebxqs.cn/news-release/2021/03/01/2184299/0/en/Qualigen-Therapeutics-Secures-Option-to-Negotiate-License-for-G-Quadruplex-Anti-Cancer-Technology-from-UCL.html Qualigen Therapeutics Secures Option to Negotiate License for G-Quadruplex Anti-Cancer Technology from UCL 2021-03-01T13:30:00Z 2021-03-05T14:17:41Z CARLSBAD, Calif., March 01, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and viral diseases, announced today it has entered into a Material Evaluation and Option Agreement with the University College London (UCL) to advance development of and potentially expand toward future commercial uses of Qualigen's leading anticancer drug candidate AS1411-GNP, also known as ALAN (Aptamer-Linked Anti-Nucleolin).

]]>
2184299 en GlobeNewswire Inc. Qualigen Therapeutics, Inc. Mon, 01 Mar 2021 13:31 GMT Health Licensing Agreements cancer viral diseases University College London pancreatic cancer oncology
http://www.yebxqs.cn/news-release/2021/03/01/2184235/0/en/Starton-Therapeutics-and-Haisco-Pharmaceutical-Announce-an-Exclusive-Licensing-Agreement-to-Develop-and-Commercialize-STAR-OLZ-for-Nausea-and-Vomiting-in-China.html Starton Therapeutics and Haisco Pharmaceutical Announce an Exclusive Licensing Agreement to Develop and Commercialize STAR-OLZ for Nausea and Vomiting in China 2021-03-01T13:00:00Z 2021-03-05T14:17:41Z PARAMUS, N.J. and CHENGDU, China, March 01, 2021 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc. (Starton), a US-based privately held clinical-stage biopharmaceutical company, and Haisco Pharmaceutical Group Co., Ltd. (Haisco), a leading China-based pharmaceutical company, announced today that they have entered into an exclusive licensing agreement for the development and commercialization of STAR-OLZ, a once-weekly transdermal olanzapine delivery system in development for Nausea and Vomiting, in Mainland China.

]]>
2184235 en GlobeNewswire Inc. Starton Therapeutics, Inc Mon, 01 Mar 2021 13:01 GMT Licensing Agreements cancer Oncology Biotechnology
http://www.yebxqs.cn/news-release/2021/03/01/2184162/0/en/VitalHub-Continues-Strong-Organic-Growth-through-Closing-Multi-Year-Licensing-Deal-with-South-Tees-Hospitals-NHS-Foundation-Trust.html VitalHub Continues Strong Organic Growth through Closing Multi-Year Licensing Deal with South Tees Hospitals NHS Foundation Trust 2021-03-01T12:30:00Z 2021-03-05T14:17:41Z TORONTO, March 01, 2021 (GLOBE NEWSWIRE) -- VitalHub Corp. (the “Company” or “VitalHub”) (TSXV: VHI) is pleased to announce a multi-year large-scale licensing transaction of recently acquired subsidiary Intouch with Health’s (“Intouch”) Synopsis product with South Tees Hospitals NHS Foundation Trust (the “Trust” or “South Tees”).

]]>
2184162 en GlobeNewswire Inc. Vitalhub Corp. Mon, 01 Mar 2021 12:30 GMT Licensing Agreements Partnerships Licensing digital health Health IT
http://www.yebxqs.cn/news-release/2021/03/01/2184138/0/ja/%E3%83%8E%E3%83%B4%E3%82%A1%E3%83%B4%E3%82%A1%E3%83%83%E3%82%AF%E3%82%B9%E3%81%A8%E6%AD%A6%E7%94%B0%E3%81%8C%E3%83%8E%E3%83%B4%E3%82%A1%E3%83%B4%E3%82%A1%E3%83%83%E3%82%AF%E3%82%B9%E3%81%AECOVID-19%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E5%80%99%E8%A3%9C%E3%81%AE%E3%83%A9%E3%82%A4%E3%82%BB%E3%83%B3%E3%82%B9%E5%A5%91%E7%B4%84%E3%82%92%E7%A2%BA%E5%AE%9A%E3%81%97-%E6%AD%A6%E7%94%B0%E3%81%AF%E6%97%A5%E6%9C%AC%E3%81%A7%E7%AC%ACI-%E7%9B%B8%E8%A9%A6%E9%A8%93%E3%82%92%E9%96%8B%E5%A7%8B.html ノヴァヴァックスと武田がノヴァヴァックスのCOVID-19ワクチン候補のライセンス契約を確定し、武田は日本で第I/Ⅱ相試験を開始 2021-03-01T12:11:42Z 2021-03-05T14:17:41Z メリーランド州ゲイザースバーグ発, March 01, 2021 (GLOBE NEWSWIRE) -- 重症感染症の次世代ワクチンを開発するバイオテクノロジー企業ノヴァヴァックス (Novavax, Inc.) (Nasdaq: NVAX) は本日、8月に発表された武田薬品工業 (Takeda Pharmaceutical Company Limited) との協力関係の進展について発表した。両社は独占ライセンス契約を締結しており、武田はノヴァヴァックスのCOVID-19ワクチン候補であるNVX-CoV2373を日本で開発、製造、販売を行う。さらに、武田は第Ⅱ相試験でノヴァヴァックスのワクチン候補の投与を開始し、日本の被験者で免疫原性と安全性を試験していく。

]]>
2184138 ja GlobeNewswire Inc. Novavax, Inc. Mon, 01 Mar 2021 12:12 GMT Company Announcement Health Licensing Agreements
http://www.yebxqs.cn/news-release/2021/02/26/2183524/0/en/Cord-Blood-Banking-Leader-Cryo-Cell-International-Enters-Into-An-Exclusive-License-Agreement-with-Duke-University.html Cord Blood Banking Leader Cryo-Cell International Enters Into An Exclusive License Agreement with Duke University 2021-02-26T14:30:00Z 2021-03-05T14:17:41Z MIAMI, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (symbol: CCEL), the world’s first private cord blood bank to separate and store stem cells, has entered into a collaborative license agreement with Duke University. The agreement grants Cryo-Cell the rights to proprietary processes and regulatory data related to cord blood and cord tissue developed at Duke.

]]>
2183524 en GlobeNewswire Inc. Cryo-Cell International, Inc. Fri, 26 Feb 2021 14:30 GMT Health Licensing Agreements HEALTH stem cell banking Cord blood banking Duke University BIOTECHNOLOGY
http://www.yebxqs.cn/news-release/2021/02/26/2183418/0/en/Novavax-and-Takeda-Finalize-License-Agreement-for-Novavax-COVID-19-Vaccine-Candidate-in-Japan-Takeda-Initiates-Phase-1-2-Trial-in-Japan.html Novavax and Takeda Finalize License Agreement for Novavax’ COVID-19 Vaccine Candidate in Japan; Takeda?Initiates Phase 1/2 Trial in Japan 2021-02-26T13:23:04Z 2021-03-05T14:17:41Z GAITHERSBURG, Md., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced progress in its collaboration with Takeda Pharmaceutical Company Limited, originally announced in August. The companies have signed an exclusive license agreement for Takeda’s development, manufacturing and commercialization of NVX-CoV2373, Novavax’ COVID-19 vaccine candidate, in Japan. Additionally, Takeda dosed the first participants in a Phase 2 clinical trial to test the immunogenicity and safety of Novavax’ vaccine candidate in the Japanese population.

]]>
2183418 en GlobeNewswire Inc. Novavax, Inc. Fri, 26 Feb 2021 13:23 GMT Company Announcement Health Licensing Agreements covid-19 vaccine trial japan
http://www.yebxqs.cn/news-release/2021/02/25/2182286/0/en/Biolojic-Design-Enters-a-Research-Collaboration-and-License-Option-Agreement-with-Nektar-Therapeutics-to-Develop-Computationally-Designed-Antibodies-Against-a-Novel-Target-for-the-.html Biolojic Design Enters a Research Collaboration and License Option Agreement with Nektar Therapeutics to Develop Computationally Designed Antibodies Against a Novel Target for the Potential Treatment of Autoimmune Disease 2021-02-25T12:00:00Z 2021-03-05T14:17:41Z TEL AVIV, Israel, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Biolojic Design (“Biolojic”), a biotechnology company that computationally designs functional antibodies, today announced that it has entered into a research collaboration and license option agreement with Nektar Therapeutics to discover and develop agonistic antibodies that activate a novel and previously un-drugged target for the treatment of autoimmune disease. Financial terms of the transaction were not disclosed.

]]>
2182286 en GlobeNewswire Inc. Biolojic Design Thu, 25 Feb 2021 12:01 GMT Licensing Agreements Partnerships
http://www.yebxqs.cn/news-release/2021/02/24/2181739/0/en/Segra-Enters-Agreement-Making-BioAgronomics-Group-s-Premium-Cannabis-Cultivar-Portfolio-Available-to-Licensed-Producers-Across-Canada-and-Select-International-Markets.html Segra Enters Agreement Making BioAgronomics Group’s Premium Cannabis Cultivar Portfolio Available to Licensed Producers Across Canada and Select International Markets 2021-02-24T17:36:53Z 2021-03-05T14:17:41Z VANCOUVER, British Columbia, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Segra International Corp., an AgTech firm focused on cannabis tissue culture and BioAgronomics Group, an internationally recognized cannabis breeding and consulting company, are pleased to announce that they have entered into an agreement to distribute numerous premium cannabis cultivars within the Canadian Market. Through decades of genetic selection and intensive breeding efforts by world-renowned industry experts, including Robert Clarke and Mojave Richmond, BioAgronomics Group has developed a portfolio of proven classic and proprietary cannabis cultivars. Now, through Segra’s Plant Tissue Culture technology, this premium genetic catalog will be available to Canadian Licensed Producers and select international markets for the first time.

]]>
2181739 en GlobeNewswire Inc. Segra International Corp. Wed, 24 Feb 2021 17:37 GMT Licensing Agreements Cannabis cannabis tissue culture Genetics genetic partner bioagronomics cannabis genetics Cannabis nursery Plant Tissue Culture
http://www.yebxqs.cn/news-release/2021/02/24/2181502/0/en/Core-Specialty-Partners-with-Duck-Creek-Technologies-for-Increased-Speed-to-Market-and-Operational-Efficiency.html Core Specialty Partners with Duck Creek Technologies for Increased Speed to Market and Operational Efficiency 2021-02-24T14:00:00Z 2021-03-05T14:17:41Z Boston, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Duck Creek Technologies (NASDAQ: DCT) announced today that Core Specialty Insurance Holdings, Inc. and its subsidiaries (“Core Specialty” or the “Company”) will implement Duck Creek’s solutions via Duck Creek OnDemand, the provider’s SaaS platform for the P&C insurance industry.

]]>
2181502 en GlobeNewswire Inc. Duck Creek Technologies Wed, 24 Feb 2021 14:00 GMT Photo


]]>
GlobeNewswire Inc.
Company Announcement Licensing Agreements Other News Product / Services Announcement Press releases Duck Creek Technologies Core Specialty Insurance Duck Creek OnDemand
粉色午夜视频/色戒未删减版在线观看视频/44383x3全国最大的免费观看/冲田杏梨番号